To evaluate the effects of intravitreal ranibizumab in myopic choroidal neovascularization (CNV).

Patients who underwent intravitreal ranibizumab injection for myopic CNV, and were followed up more than 6 months, and their records were retrospectively investigated. The best corrected visual acuity, central macular thickness, and leak in fluorescein angiography were compared at baseline, and at 1, 3, and 6 months after injection.

Twenty-one eyes of 18 patients were evaluated. The mean best corrected visual acuity (logMAR) was 1.23±0.65, 0.96± 0.40, 0.95±0.67, and 0.83±0.58 at baseline, 1, 3, and 6 months, respectively ( p <0.001, p =0.006, p =0.001). The mean central macular thickness was 233.42±65.55 µm, 204.14±65.29 µm, and 157.76±71.45 µm at baseline, 3, and 6 months, respectively ( p <0.001). In fluorescein angiography at 6 months after injection, regression was observed in 12 eyes, and fibrosis in 9 eyes.

Intravitreal ranibizumab injection for myopic CNV in Korean patients appeared to be effective, resulting in regression of lesion and improvement of visual acuity.